OBJECTIVES: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. METHODS: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. RESULTS: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. CONCLUSION: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.
OBJECTIVES: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. METHODS: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. RESULTS: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. CONCLUSION: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.
Entities:
Keywords:
Acquired hemophilia A; bleeding; eradication therapy; factor VIII
Authors: Katharina Holstein; Xiaofei Liu; Andrea Smith; Paul Knöbl; Robert Klamroth; Ulrich Geisen; Hermann Eichler; Wolfgang Miesbach; Andreas Tiede Journal: Blood Date: 2020-07-16 Impact factor: 22.113
Authors: José María Bastida; María Teresa Cano-Mozo; Felix Lopez-Cadenas; Victor Eduardo Vallejo; Soraya Merchán; Cecilia Santos-Montón; David González-Calle; Javier Carrillo; Ana Africa Martín; Jose Angel Torres-Hernández; Marcos González; Francisco Martín-Herrero; Pedro Pabón; Jose Ramon González-Porras Journal: Medicine (Baltimore) Date: 2017-11 Impact factor: 1.817